SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sanne Dam-Larsen, Bahman Darkahi, Arne Glad, Dagfinn Gleditsch, Lena Gustavsson, Jorma Halttunen, Karl Erik Johansson, Andreas Pischel, Ola Reiertsen, Björn Törnqvist, Hubert Zebski, Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson’s disease in the Nordic region, Scandinavian Journal of Gastroenterology, 2015, 1

    CrossRef

  2. 2
    Evelyn Walter, Per Odin, Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany, Journal of Medical Economics, 2015, 18, 2, 155

    CrossRef

  3. 3
    Mark F. Lew, John T. Slevin, Rejko Krüger, Juan Carlos Martínez Castrillo, Krai Chatamra, Jordan S. Dubow, Weining Z. Robieson, Janet A. Benesh, Victor S.C. Fung, Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials, Parkinsonism & Related Disorders, 2015, 21, 7, 742

    CrossRef

  4. 4
    Hubert H. Fernandez, David G. Standaert, Robert A. Hauser, Anthony E. Lang, Victor S.C. Fung, Fabian Klostermann, Mark F. Lew, Per Odin, Malcolm Steiger, Eduard Z. Yakupov, Sylvain Chouinard, Oksana Suchowersky, Jordan Dubow, Coleen M. Hall, Krai Chatamra, Weining Z. Robieson, Janet A. Benesh, Alberto J. Espay, Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results, Movement Disorders, 2015, 30, 4
  5. 5
    Oluwadamilola O Ojo, Hubert H Fernandez, Levodopa/carbidopa intestinal gel: an effective formulation for the management of advanced Parkinson's disease, Future Neurology, 2015, 10, 3, 191

    CrossRef

  6. 6
    Maríateresa Buongiorno, Francesca Antonelli, Ana Cámara, Victor Puente, Oriol de Fabregues-Nebot, Jorge Hernandez-Vara, Matilde Calopa, Berta Pascual-Sedano, Antonia Campolongo, Francesc Valldeoriola, Eduardo Tolosa, Jaime Kulisevsky, Maria Jose Martí, Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry, Parkinsonism & Related Disorders, 2015, 21, 8, 871

    CrossRef

  7. 7
    Werner Poewe, Angelo Antonini, Novel formulations and modes of delivery of levodopa, Movement Disorders, 2015, 30, 1
  8. 8
    Matthieu F. Bastide, Wassilios G. Meissner, Barbara Picconi, Stefania Fasano, Pierre-Olivier Fernagut, Michael Feyder, Veronica Francardo, Cristina Alcacer, Yunmin Ding, Riccardo Brambilla, Gilberto Fisone, A. Jon Stoessl, Mathieu Bourdenx, Michel Engeln, Sylvia Navailles, Philippe De Deurwaerdère, Wai Kin D. Ko, Nicola Simola, Micaela Morelli, Laurent Groc, Maria-Cruz Rodriguez, Eugenia V. Gurevich, Maryka Quik, Michele Morari, Manuela Mellone, Fabrizio Gardoni, Elisabetta Tronci, Dominique Guehl, François Tison, Alan R. Crossman, Un Jung Kang, Kathy Steece-Collier, Susan Fox, Manolo Carta, M. Angela Cenci, Erwan Bézard, Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease, Progress in Neurobiology, 2015,

    CrossRef

  9. 9
    Antonino Uncini, Roberto Eleopra, Marco Onofrj, Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management, Journal of Neurology, Neurosurgery & Psychiatry, 2015, 86, 5, 490

    CrossRef

  10. 10
    C Warren Olanow, Karl Kieburtz, Per Odin, Alberto J Espay, David G Standaert, Hubert H Fernandez, Arvydas Vanagunas, Ahmed A Othman, Katherine L Widnell, Weining Z Robieson, Yili Pritchett, Krai Chatamra, Janet Benesh, Robert A Lenz, Angelo Antonini, Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study, The Lancet Neurology, 2014, 13, 2, 141

    CrossRef

  11. 11
    Mariachiara Sensi, F. Preda, L. Trevisani, E. Contini, D. Gragnaniello, J. G. Capone, E. Sette, N. Golfre-Andreasi, V. Tugnoli, M. R. Tola, R. Quatrale, Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients, Journal of Neural Transmission, 2014, 121, 6, 633

    CrossRef

  12. 12
    F.I. Tarazi, Z.T. Sahli, M. Wolny, S.A. Mousa, Emerging therapies for Parkinson's disease: From bench to bedside, Pharmacology & Therapeutics, 2014, 144, 2, 123

    CrossRef

  13. 13
    Pantelis Stathis, Vasilios Tzias, Pavlos Argyris, Georgia Barla, Maria Maltezou, Gastric bezoar complication of Duodopa® therapy in Parkinson's disease, treated with Coca-Cola®, Movement Disorders, 2014, 29, 8
  14. 14
    Imke Galazky, Julia Schoof, Sabine Stallforth, Andreas Kupsch, Hans-Jochen Heinze, Christian Kluge, Guillain–Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment, Parkinsonism & Related Disorders, 2014, 20, 1, 125

    CrossRef

  15. 15
    María T. Cáceres-Redondo, Fátima Carrillo, María J. Lama, Ismael Huertas-Fernández, Laura Vargas-González, Manuel Carballo, Pablo Mir, Long-term levodopa/carbidopa intestinal gel in advanced Parkinson’s disease, Journal of Neurology, 2014, 261, 3, 561

    CrossRef

  16. 16
    C. Comi, L. Magistrelli, G.D. Oggioni, M. Carecchio, T. Fleetwood, R. Cantello, F. Mancini, A. Antonini, Peripheral nervous system involvement in Parkinson's disease: Evidence and controversies, Parkinsonism & Related Disorders, 2014, 20, 12, 1329

    CrossRef

  17. 17
    F. Mancini, C. Comi, G.D. Oggioni, C. Pacchetti, D. Calandrella, M. Coletti Moja, G. Riboldazzi, S. Tunesi, M. Dal Fante, L. Manfredi, M. Lacerenza, R. Cantello, A. Antonini, Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens, Parkinsonism & Related Disorders, 2014, 20, 1, 27

    CrossRef

  18. 18
    A. Merola, M. Zibetti, M. G. Rizzone, M. Troiano, C. A. Artusi, S. Angrisano, D. Cocito, L. Lopiano, Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients, Acta Neurologica Scandinavica, 2014, 129, 1
  19. 19
    Livia Dézsi, László Vécsei, Safinamide for the treatment of Parkinson's disease, Expert Opinion on Investigational Drugs, 2014, 23, 5, 729

    CrossRef

  20. 20
    Sophie M. Lehnerer, Urban M. Fietzek, Michael Messner, Andres O. Ceballos-Baumann, Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation, Journal of Neural Transmission, 2014, 121, 10, 1269

    CrossRef

  21. 21
    Philip C. Buttery, Roger A. Barker, Treating Parkinson's disease in the 21st century: Can stem cell transplantation compete?, Journal of Comparative Neurology, 2014, 522, 12
  22. 22
    Wolfgang H Jost, Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration, Expert Opinion on Drug Safety, 2014, 13, 4, 447

    CrossRef

  23. 23
    Monika Pötter-Nerger, Peter Ludewig, Ute Hidding, Ines Goerendt, Christian Gerloff, Carsten Buhmann, Wann sind Pflaster, Pens oder Pumpen eine sinnvolle Ergänzung zur oralen Therapie?, InFo Neurologie & Psychiatrie, 2014, 16, 12, 42

    CrossRef

  24. 24
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Advanced Parkinson's disease: Clinical characteristics and treatment. Part II, Neurología (English Edition), 2013, 28, 9, 558

    CrossRef

  25. 25
    Brenton A Wright, Cheryl H Waters, Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease, Expert Review of Neurotherapeutics, 2013, 13, 6, 719

    CrossRef

  26. 26
    Francesc Valldeoriola, Jaume Puig-Junoy, Ruth Puig-Peiró, Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study, Journal of Medical Economics, 2013, 16, 2, 191

    CrossRef

  27. 27
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II, Neurología, 2013, 28, 9, 558

    CrossRef

  28. 28
    Robert A Hauser, Ann Hsu, Sherron Kell, Alberto J Espay, Kapil Sethi, Mark Stacy, William Ondo, Martin O'Connell, Suneel Gupta, Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial, The Lancet Neurology, 2013, 12, 4, 346

    CrossRef

  29. 29
    T. Foltynie, C. Magee, C. James, G. J. M. Webster, A. J. Lees, P. Limousin, Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series, Parkinson's Disease, 2013, 2013, 1

    CrossRef

  30. 30
    Barbara Anne Pickut, Chris van der Linden, Sophie Dethy, Hilde Van De Maele, Diederik Zegers de Beyl, Intestinal levodopa infusion: the Belgian experience, Neurological Sciences, 2013,

    CrossRef

  31. 31
    Maria Papathanou, Rika Laan, Peter Jenner, Sarah Rose, Andrew C. McCreary, Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats, Movement Disorders, 2013, 28, 8
  32. 32
    Maurizio Zibetti, Aristide Merola, Valeria Ricchi, Alice Marchisio, Carlo Alberto Artusi, Laura Rizzi, Elisa Montanaro, Dario Reggio, Claudio Angelis, Mario Rizzone, Leonardo Lopiano, Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study, Journal of Neurology, 2013, 260, 1, 105

    CrossRef

  33. 33
    Fabienne Sprenger, Werner Poewe, Management of Motor and Non-Motor Symptoms in Parkinson’s Disease, CNS Drugs, 2013, 27, 4, 259

    CrossRef

  34. 34
    K. Ray Chaudhuri, Alexandra Rizos, Kapil D. Sethi, Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?, Journal of Neural Transmission, 2013, 120, 9, 1305

    CrossRef

  35. 35
    Thomas Müller, Teus van Laar, David R. Cornblath, Per Odin, Fabian Klostermann, Francisco J. Grandas, Georg Ebersbach, Peter P. Urban, Francesc Valldeoriola, Angelo Antonini, Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery, Parkinsonism & Related Disorders, 2013, 19, 5, 501

    CrossRef

  36. 36
    Sabine Skodda, Thomas Müller, Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson’s disease under duodopa® therapy, Journal of Neural Transmission, 2013, 120, 2, 315

    CrossRef

  37. 37
    M. Zibetti, M. Rizzone, A. Merola, S. Angrisano, L. Rizzi, E. Montanaro, A. Cicolin, L. Lopiano, Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease, Acta Neurologica Scandinavica, 2013, 127, 5
  38. You have free access to this content38
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  39. 39
    Sophie Drapier, Anne-Sophie Gillioz, Emmanuelle Leray, Julie Péron, Tiphaine Rouaud, Annaig Marchand, Marc Vérin, Apomorphine infusion in advanced Parkinson’s patients with subthalamic stimulation contraindications, Parkinsonism & Related Disorders, 2012, 18, 1, 40

    CrossRef

  40. 40
    J. Guridi, R. González-Redondo, J. A. Obeso, Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  41. 41
    Anders Johansson, Dag Nyholm, Continuous delivery of energy or L-dopa: Identifying advantages and limitations of DBS and levodopa–carbidopa intestinal gel in the absence of head-to-head comparisons, Basal Ganglia, 2012, 2, 4, 221

    CrossRef

  42. 42
    D. Santos-García, M. J. Añón, L. Fuster-Sanjurjo, R. de la Fuente-Fernández, Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson’s disease leads to improvement in caregivers’ stress and burden, European Journal of Neurology, 2012, 19, 9
  43. 43
    Dag Nyholm, Duodopa® treatment for advanced Parkinson's disease: A review of efficacy and safety, Parkinsonism & Related Disorders, 2012, 18, 8, 916

    CrossRef

  44. 44
    S. E. Pålhagen, N. Dizdar, T. Hauge, B. Holmberg, R. Jansson, J. Linder, D. Nyholm, O. Sydow, M. Wainwright, H. Widner, A. Johansson, Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease, Acta Neurologica Scandinavica, 2012, 126, 6
  45. 45
    Prashanth Reddy, Pablo Martinez-Martin, Alexandra Rizos, Anne Martin, Guy C. Faye, Ian Forgacs, Per Odin, Angelo Antonini, K. Ray Chaudhuri, Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease, Clinical Neuropharmacology, 2012, 35, 5, 205

    CrossRef

  46. 46
    D. Santos-García, L. F. Sanjurjo, M. Macías, M. Llaneza, P. Carpintero, R. de la Fuente-Fernández, Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being, Acta Neurologica Scandinavica, 2012, 125, 3
  47. 47
    Fabian Klostermann, Constanze Jugel, Thomas Müller, Frank Marzinzik, Malnutritional neuropathy under intestinal levodopa infusion, Journal of Neural Transmission, 2012, 119, 3, 369

    CrossRef

  48. 48
    A. E. Elia, C. Dollenz, P. Soliveri, A. Albanese, Motor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulation, European Journal of Neurology, 2012, 19, 1
  49. 49
    Diego Santos-García, Raúl de la Fuente-Fernández, Francesc Valldeoriola, Antonio Palasí, Fátima Carrillo, Mónica Grande, Pablo Mir, Oriol De Fabregues, Jordi Casanova, Polyneuropathy while on duodenal levodopa infusion in Parkinson’s disease patients: we must be alert, Journal of Neurology, 2012, 259, 8, 1668

    CrossRef

  50. 50
    Aiping Wang, Lexi Wang, Kaoxiang Sun, Wanhui Liu, Chunjie Sha, Youxin Li, Preparation of Rotigotine-Loaded Microspheres and Their Combination Use with L-DOPA to Modify Dyskinesias in 6-OHDA-Lesioned Rats, Pharmaceutical Research, 2012, 29, 9, 2367

    CrossRef

  51. 51
    A. Munro Neville, Richard W. Parsons, Håkan Askmark, Dag Nyholm, Treatment of advanced Parkinson’s disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage, Parkinsonism & Related Disorders, 2012, 18, 5, 686

    CrossRef

  52. 52
    Suja Sadasivan, Joseph H Friedman, Vitamin B12 (cobalamin) and Parkinson’s disease, Clinical Practice, 2012, 9, 4, 353

    CrossRef

  53. 53
    Julia Lowin, Annika Bergman, K. Ray Chaudhuri, Leslie J. Findley, Claudia Roeder, Mathias Schifflers, Eifiona Wood, Stephen Morris, A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK, Journal of Medical Economics, 2011, 14, 5, 584

    CrossRef

  54. 54
    Fabian Klostermann, Constanze Jugel, Frank Marzinzik, Benefit from jejunal levodopa in a patient with apomorphine pump, Journal of Neurology, 2011, 258, 2, 311

    CrossRef

  55. 55
    Aristide Merola, Maurizio Zibetti, Serena Angrisano, Laura Rizzi, Michele Lanotte, Leonardo Lopiano, Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease, Movement Disorders, 2011, 26, 4
  56. 56
    Maria Cruz Rodriguez-Oroz, Concepción Marin, Oriol de Fabregues, Continuous Dopaminergic Stimulation, The Neurologist, 2011, 17, S30

    CrossRef

  57. 57
    P. Jenner, A. C. McCreary, D. K. A. Scheller, Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression, Journal of Neural Transmission, 2011, 118, 12, 1691

    CrossRef

  58. 58
    Robert A. Hauser, Future Treatments for Parkinson's Disease: Surfing the PD Pipeline, International Journal of Neuroscience, 2011, 121, S2, 53

    CrossRef

  59. 59
    R. Carron, V. Fraix, C. Maineri, E. Seigneuret, B. Piallat, P. Krack, P. Pollak, A. L. Benabid, Stéphan Chabardès, High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review, Journal of Neural Transmission, 2011, 118, 6, 915

    CrossRef

  60. 60
    H.H. Fernandez, P. Odin, Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease, Current Medical Research and Opinion, 2011, 27, 5, 907

    CrossRef

  61. 61
    Olivier Rascol, Andres Lozano, Matthew Stern, Werner Poewe, Milestones in Parkinson's disease therapeutics, Movement Disorders, 2011, 26, 6
  62. 62
    Lawrence Elmer, Robert A Hauser, Strategies for Parkinson’s disease care: prevention and management of motor fluctuations, Neurodegenerative Disease Management, 2011, 1, 5, 415

    CrossRef

  63. 63
    S. Maranis, S. Tsouli, S. Konitsiotis, Treatment of motor symptoms in advanced Parkinson's disease: A practical approach, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 8, 1795

    CrossRef

  64. 64
    Angelo Antonini, Pablo Martinez-Martin, Ray K. Chaudhuri, Marcelo Merello, Robert Hauser, Regina Katzenschlager, Per Odin, Mark Stacy, Fabrizio Stocchi, Werner Poewe, Oliver Rascol, Cristina Sampaio, Anette Schrag, Glenn T. Stebbins, Christopher G. Goetz, Wearing-off scales in Parkinson's disease: Critique and recommendations, Movement Disorders, 2011, 26, 12
  65. 65
    Rüdiger Hilker, Angelo Antonini, Per Odin, What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?, Journal of Neural Transmission, 2011, 118, 6, 907

    CrossRef

  66. 66
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  67. 67
    Andrzej Bogucki, Jarosław Sławek, Ciągła stymulacja dopaminergiczna – doświadczenia kliniczne, Neurologia i Neurochirurgia Polska, 2010, 44, 4, 385

    CrossRef

  68. 68
    J.C. Sharma, C.G. Bachmann, G. Linazasoro, Classifying risk factors for dyskinesia in Parkinson’s disease, Parkinsonism & Related Disorders, 2010, 16, 8, 490

    CrossRef

  69. 69
    Angelo Antonini, Giulia Ursino, Daniela Calandrella, Laura Bernardi, Mauro Plebani, Continuous dopaminergic delivery in Parkinson’s disease, Journal of Neurology, 2010, 257, S2, 305

    CrossRef

  70. 70
    K.A. Stockwell, D.K.A. Scheller, L.A. Smith, S. Rose, M.M. Iravani, M.J. Jackson, P. Jenner, Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets, Experimental Neurology, 2010, 221, 1, 79

    CrossRef

  71. 71
    Jarosław Sławek, Andrzej Bogucki, Dojelitowa postać lewodopy w leczeniu zaawansowanej choroby Parkinsona, Neurologia i Neurochirurgia Polska, 2010, 44, 4, 396

    CrossRef

  72. 72
    V. Puente, O. De Fabregues, C. Oliveras, G. Ribera, C. Pont-Sunyer, R. Vivanco, G. Cucurella, E. Giralt, T. Delgado, C. Garcia, A. Seoane, R. Campo, Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life, Parkinsonism & Related Disorders, 2010, 16, 3, 218

    CrossRef

  73. 73
    D. Santos-García, M. Macías, M. Llaneza, L. Fuster-Sanjurjo, A. Echarri-Piudo, S. Belmonte, S. Blanco, Experience with continuous levodopa enteral infusion (Duodopa®)in patients with advanced Parkinson's disease in a secondary level hospital, Neurología (English Edition), 2010, 25, 9, 536

    CrossRef

  74. 74
    D. Santos-García, M. Macías, M. LLaneza, L. Fuster-Sanjurjo, A. Echarri-Piudo, S. Belmonte, S. Blanco, Experiencia con la infusión continua de levodopa intraduodenal (Duodopa®) en pacientes con enfermedad de Parkinson avanzada en un hospital de segundo nivel asistencial, Neurología, 2010, 25, 9, 536

    CrossRef

  75. 75
    Fabrizio Stocchi, Olivier Rascol, Karl Kieburtz, Werner Poewe, Joseph Jankovic, Eduardo Tolosa, Paulo Barone, Anthony E. Lang, C. Warren Olanow, Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study, Annals of Neurology, 2010, 68, 1
  76. 76
    Martin Wolz, Matthias Löhle, Karl Strecker, Uta Schwanebeck, Christine Schneider, Heinz Reichmann, Xina Grählert, Johannes Schwarz, Alexander Storch, Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial, Journal of Neural Transmission, 2010, 117, 11, 1279

    CrossRef

  77. 77
    A. Antonini, G. Bondiolotti, F. Natuzzi, S.R. Bareggi, Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa, European Neuropsychopharmacology, 2010, 20, 10, 683

    CrossRef

  78. 78
    Gianni Pezzoli, Michela Zini, Levodopa in Parkinson's disease: from the past to the future, Expert Opinion on Pharmacotherapy, 2010, 11, 4, 627

    CrossRef

  79. 79
    Angelo Antonini, K. Ray Chaudhuri, Pablo Martinez-Martin, Per Odin, Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinsonʼs Disease, CNS Drugs, 2010, 24, 2, 119

    CrossRef

  80. 80
    Stanley Fahn, Parkinson's disease: 10 years of progress, 1997–2007, Movement Disorders, 2010, 25, S1
  81. 81
    Michael Willis, Ulf Persson, York Zoellner, Birgit Gradl, Reducing Uncertainty in Value-Based Pricing Using Evidence Development Agreements, Applied Health Economics and Health Policy, 2010, 8, 6, 377

    CrossRef

  82. 82
    Peter P. Urban, Ingmar Wellach, Siegbert Faiss, Peter Layer, Thorsten Rosenkranz, Karl Knop, Joachim Weis, Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy, Movement Disorders, 2010, 25, 11
  83. 83
    Alessandro Stefani, Mariangela Pierantozzi, Giacomo Koch, Salvatore Galati, Paolo Stanzione, Therapy for dyskinesias in Parkinson’s disease patients, Future Neurology, 2010, 5, 2, 277

    CrossRef

  84. 84
    Sara Varanese, Zoe Birnbaum, Roger Rossi, Alessandro Di Rocco, Treatment of Advanced Parkinson's Disease, Parkinson's Disease, 2010, 2010, 1

    CrossRef

  85. 85
    Angelo Antonini, Eduardo Tolosa, Yoshikuni Mizuno, Mitsutoshi Yamamoto, Werner H Poewe, A reassessment of risks and benefits of dopamine agonists in Parkinson's disease, The Lancet Neurology, 2009, 8, 10, 929

    CrossRef

  86. 86
    Angelo Antonini, Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease, Journal of Movement Disorders, 2009, 2, 1, 4

    CrossRef

  87. 87
    Angelo Antonini, Eduardo Tolosa, Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management, Expert Review of Neurotherapeutics, 2009, 9, 6, 859

    CrossRef

  88. 88
    Marco Onofrj, Laura Bonanni, Giovanni Cossu, Davide Manca, Fabrizio Stocchi, Astrid Thomas, Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment, Parkinsonism & Related Disorders, 2009, 15, S233

    CrossRef

  89. 89
    A. Annic, D. Devos, D. Seguy, K. Dujardin, A. Destée, L. Defebvre, Intérêts de la stimulation dopaminergique continue par Duodopa® dans la maladie de Parkinson évoluée : efficacité et tolérance, Revue Neurologique, 2009, 165, 8-9, 718

    CrossRef

  90. 90
    Holger Honig, Angelo Antonini, Pablo Martinez-Martin, Ian Forgacs, Guy C. Faye, Thomas Fox, Karen Fox, Francesca Mancini, Margherita Canesi, Per Odin, K. Ray Chaudhuri, Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life, Movement Disorders, 2009, 24, 10
  91. 91
    A. H. V. Schapira, M. Emre, P. Jenner, W. Poewe, Levodopa in the treatment of Parkinson’s disease, European Journal of Neurology, 2009, 16, 9
  92. 92
    David Devos, Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease, Movement Disorders, 2009, 24, 7
  93. 93
    A. H. Schapira, Y. Agid, P. Barone, P. Jenner, M. R. Lemke, W. Poewe, O. Rascol, H. Reichmann, E. Tolosa, Perspectives on recent advances in the understanding and treatment of Parkinson’s disease, European Journal of Neurology, 2009, 16, 10
  94. 94
    Angelo Antonini, Per Odin, Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, S97

    CrossRef

  95. 95
    Davide Manca, Giovanni Cossu, Daniela Murgia, Andrea Molari, Paola Ferrigno, Emanuele Marcia, Maurizio Melis, Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy, Movement Disorders, 2009, 24, 15
  96. 96
    Carl E. Clarke, Paul Worth, Donald Grosset, David Stewart, Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, 10, 728

    CrossRef

  97. 97
    Per Odin, Erik Wolters, Angelo Antonini, Continuous dopaminergic stimulation achieved by duodenal levodopa infusion, Neurological Sciences, 2008, 29, S5, 387

    CrossRef

  98. 98
    A. Antonini, F. Mancini, M. Canesi, R. Zangaglia, I.U. Isaias, L. Manfredi, C. Pacchetti, M. Zibetti, F. Natuzzi, L. Lopiano, G. Nappi, G. Pezzoli, Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson’s Disease, Neurodegenerative Diseases, 2008, 5, 3-4, 244

    CrossRef

  99. 99
    D. Isacson, K. Bingefors, I. S. Kristiansen, D. Nyholm, Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion, Acta Neurologica Scandinavica, 2008, 118, 6
  100. 100
    Stanley Fahn, How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?, Annals of Neurology, 2008, 64, S2
  101. 101
    David A Gallagher, Anette Schrag, Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease, CNS Drugs, 2008, 22, 7, 563

    CrossRef

  102. 102
    Francesca Sorbo, Alberto Albanese, Levodopa-induced dyskinesias and their management, Journal of Neurology, 2008, 255, S4, 32

    CrossRef

  103. 103
    C. Warren Olanow, Levodopa/dopamine replacement strategies in Parkinson's disease—Future directions, Movement Disorders, 2008, 23, S3
  104. 104
    Olof Sydow, Parkinson’s disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion, FEBS Journal, 2008, 275, 7
  105. 105
    Pablo Martinez-Martin, Carmen Rodriguez-Blazquez, Belen Frades-Payo, Specific patient-reported outcome measures for Parkinson’s disease: analysis and applications, Expert Review of Pharmacoeconomics & Outcomes Research, 2008, 8, 4, 401

    CrossRef

  106. 106
    A.D. Korczyn, International Encyclopedia of Public Health, 2008,

    CrossRef

  107. 107
    Angelo Antonini, New strategies in motor parkinsonism, Parkinsonism & Related Disorders, 2007, 13, S446

    CrossRef

  108. 108
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Late (Complicated) Parkinson's Disease,